Education
About Us
Working with TipRanks
Follow Us
cbdMD (YCBD)
XASE:YCBD
YCBD Stock Chart & Stats
$0.90
$0.03(3.20%)
At close: 4:00 PM EST
$0.90
$0.03(3.20%)
Day’s Range― - ―
52-Week Range$0.47 - $3.36
Previous CloseN/A
Volume6.20K
Average Volume (3M)7.54M
Market Cap
$8.52M
Enterprise Value$597.95M
Total Cash (Recent Filing)$3.39M
Total Debt (Recent Filing)$593.03M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
May 20, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding10,495,561
10 Day Avg. Volume860,286
30 Day Avg. Volume7,543,844
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.67
Price to Sales (P/S)0.25
P/FCF Ratio-2.97
Enterprise Value/Market Cap70.16
Enterprise Value/Revenue31.32
Enterprise Value/Gross Profit56.97
Enterprise Value/Ebitda-1.22K
Forecast
1Y Price Target
$2.00Price Target Upside122.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.22
Revenue Forecast (FY)$19.54M
Bulls Say, Bears Say
Bulls Say
Acquisition And Regulatory IntegrationAnalyst views the acquisition of Bluebird Botanicals as strategic because it brings a premium hemp-derived CBD brand with an established e-commerce customer base and regulatory and scientific assets that strengthen competitive positioning amid regulatory uncertainty.
Distribution Expansion And Product InnovationAnalyst notes expanded distribution of the Herbal Oasis THC-infused seltzer portfolio into new regions and product innovation should broaden retail reach and support top-line growth.
Operating Stabilization And Cost RealignmentAnalyst sees operating stabilization after a company transformation that lowered fixed costs, reduced balance-sheet risk, and realigned SKUs toward higher-demand, higher-margin products, improving the profitability outlook.
Bears Say
Legislative Risk To THC Product SalesAnalyst warns that H.R. 5371 could materially disrupt sales of certain THC-containing SKUs, including Herbal Oasis seltzers, creating downside risk to revenue in affected retail channels.
Liquidity RiskAnalyst flags a constrained cash position that could limit operational flexibility, although access to a committed credit line may extend the company's financial runway.
cbdMD News
YCBD FAQ
What was cbdMD’s price range in the past 12 months?
cbdMD lowest stock price was $0.47 and its highest was $3.36 in the past 12 months.
What is cbdMD’s market cap?
cbdMD’s market cap is $8.52M.
When is cbdMD’s upcoming earnings report date?
cbdMD’s upcoming earnings report date is May 20, 2026 which is in 77 days.
How were cbdMD’s earnings last quarter?
cbdMD released its earnings results on Feb 17, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.06 by $0.02.
Is cbdMD overvalued?
According to Wall Street analysts cbdMD’s price is currently Undervalued.
Does cbdMD pay dividends?
cbdMD does not currently pay dividends.
What is cbdMD’s EPS estimate?
cbdMD’s EPS estimate is -0.05.
How many shares outstanding does cbdMD have?
cbdMD has 10,495,561 shares outstanding.
What happened to cbdMD’s price movement after its last earnings report?
cbdMD reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.06. Following the earnings report the stock price went down -6.83%.
Which hedge fund is a major shareholder of cbdMD?
Currently, no hedge funds are holding shares in YCBD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
cbdMD
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.
YCBD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed cautious optimism: management highlighted sequential revenue growth (12% QoQ), wholesale momentum (~17% increase), near-breakeven adjusted EBITDA (~$36K loss), a strategic acquisition (Bluebird Botanicals) expected to add revenue and IP, and improved liquidity via a ~$2.25M Series C and a $20M ELOC. Counterbalancing these positives are modest YoY revenue decline (~2%), gross margin compression (down 6 percentage points to 60%), a widened operating loss (~$286K), and ongoing regulatory headwinds that created customer confusion and added compliance costs. On balance, the operational progress, balance sheet improvements, and strategic acquisition slightly outweigh the challenges, supporting a constructive outlook while acknowledging execution and regulatory risks remain.View all YCBD earnings summariesYCBD Stock 12 Month Forecast
Average Price Target
$2.00
▲(122.97% Upside)
Technical Analysis
Ownership Overview
14.96% Insiders
0.50% Mutual Funds
1.57% Other Institutional Investors
82.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---